Affiliation:
1. Department of Physical Medicine Alexandria University Egypt
2. Arthritis‐Immunology Center Philadelphia Pennsylvania USA
Abstract
SUMMARYBetter understanding of the immunopathogenesis of rheumatoid arthritis over the past few decades has promoted the innovation of new therapeutic approaches targeting the disease more specifically. In addition, refinements in the non‐steroidal anti‐inflammatory drugs (NSAID) may offer advantages for patients with RA. This brief review reports and analyses some of the important aspects of these new therapies available for treatment of RA and in which situations you might consider each. Before using any of these agents, physicians should become thoroughly familiar with the package inserts.
Reference26 articles.
1. Regulation of STNF and IL‐6 following TNF blockade in RA; in vivo evidence for a cytokine cascade;Charles P;Arthritis Rheum,1995
2. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
3. INHIBITORY EFFECT OF TNF$alpha; ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS
4. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of TNFα with the IL‐1 receptor antagonist;Butler DM;Eur Cytokine Netw,1995
5. ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS